US0231112063 - ADR
AMARIN CORP PLC -ADR
NASDAQ:AMRN (5/8/2024, 2:52:04 PM)
0.8755
-0.1 (-10.21%)
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
AMARIN CORP PLC -ADR
First Floor, Block 3, The Oval,, Shelbourne Road, Ballsbridge
DUBLIN Dublin 2
P: 35316699020
CEO: John F. Thero
Employees: 365
Website: https://amarincorp.com/
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s...
AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
AMRN earnings call for the period ending March 31, 2024.
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue...
Here you can normally see the latest stock twits on AMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: